SlideShare a Scribd company logo
Scientific innovations
for more sustainable
growth
Copyright © 2022 Accenture. All rights reserved.
The Situation
The pace of innovation in life sciences
is at an all time high with unprecedented
scientific development in many areas. It’s just
the beginning of a significant and lasting shift.
With rising M&A costs, increasing pressures on
profitability, biotechs bringing products to
market themselves, and increasing pressures on
profitability, the entire landscape for biopharma
has shifted to an environment that requires
innovative and strategic approaches to
maintain pace.
But how can biopharma companies
sustain growth?
To better understand this challenge and determine pathways for success we conducted an extensive
analysis of over 300 M&A deals made by the top 30 biopharma companies between 2010 2021.
The key takeaway:
The traditional approach to fostering growth is no longer sustainable.
The Analysis
The good news is that there are clear pathways that biopharma companies can take
to remain competitive.
Rising Costs of Inorganic Growth:
1
Biotech transaction premiums reached record highs in 2021,
making inorganic growth increasingly expensive.
For M&A deals valued at more than $500M, the average takeout
premium in biopharma has grown from 51% in 2018 to roughly 71%
in 2021.1
In Q1 2022, public markets slowed with biotech performance dropping
and capital raised decreasing. Nevertheless, private markets remain
healthy with total VC investment in Q1 2022 being the second-largest
quarter of all time (after Q1 2021) for biotech-venture capital funding.2
How did we get here?
3 Factors eroding the sustainability of an inorganic growth strategy that relies heavily on M&A
1Accenture Research leveraging evaluate Pharma data. March 2022.
2Accenture Research leveraging evaluate Pharma data. April 2022.
Copyright © 2022 Accenture. All rights reserved. 4
4
Biotech going to market alone:
2
Smaller biotech companies are increasingly able to bring their products
to market themselves.
These players were responsible for approximately 55% of all drugs
brought to market between 2017 and 2021 a significant increase from
the preceding five year period (2012 2016) in which they accounted for
only 30%.3
Continued venture capital flow to biotechs noted above, further fuels
the escalating deal premiums.
How did we get here?
3 Factors eroding the sustainability of an inorganic growth strategy that relies heavily on M&A
3Accenture Research leveraging evaluate Pharma data. March 2022.
Copyright © 2022 Accenture. All rights reserved. 5
5
Increasing profitability pressures:
3
Margin declines in almost every therapeutic area is expected to be over
6% on average, with anti infectives expected to experience the largest
decline at 11.6%.4
A further decline in future revenues is also expected due to potential
U.S. policy reforms.
How did we get here?
3 Factors eroding the sustainability of an inorganic growth strategy that relies heavily on M&A
4New Science: A new economic reality for innovation and growth. Accenture 2021.
Copyright © 2022 Accenture. All rights reserved. 6
6
Assessing the options
Source: Accenture Research Growth Pathways Model 2021.
An analysis of all M&A transactions of top 30 biopharma companies by revenue,
leveraging S&P Cap IQ data. Percentages were calculated based on # of transactions.
Inorganic growth pathways: 2010-2021, number of transactions
36% 34% 16% 14%
Controller
geographic expansion
or vertical integration
Ecosystem
acquisitions of
know-how and
capabilities to
innovate faster
or reach customers
in new ways
Builder
bolt-on-late-stage
asset acquisitions
Architect
early-stage asset
acquisitions often with a
biotechnology platform
Through our analysis, we identified four growth pathways for biopharma companies. By
understanding these pathways, we can better anticipate trends toward innovation and success:
1. Architect:
Shift away from early-stage
assets towards platform-based
deals.
2. Builder:
Fewer asset-based Builder
pathways.
3. Ecosystem and Controller:
More Ecosystem and Controller
pathways thanks to nearly
unlimited funding from VC and
PE as well as increasing
opportunities ex-US.
Growth Pathways Predictions
Source: Accenture Research Growth Pathways Model 2021.
An analysis of all M&A transactions of top 30 biopharma companies by revenue, leveraging S&P Cap IQ data.
Percentages were calculated based on # of transactions.
Inorganic growth pathways: 2010-2021, number of transactions
36% 34% 16% 14%
Fewer late-stage
asset-based Builder
pathways.
35% 15% 25% 25%
Future (illustrative)
Architect
Early-stage asset
acquisitions often
with a biotechnology
platform
Builder
Bolt-on-late-
stage asset
acquisitions
Ecosystem
Acquisitions of
know-how and
capabilities to
innovate faster or
reach customers
in new ways
Controller
Geographic
expansion
or vertical
integration
Shift away from
early-stage assets
and towards
platform-based
deals.
More Ecosystem and Controller
pathways thanks to nearly unlimited
funding from VC and PE as well as
increasing opportunities ex-US.
Predictions
70% of all deals in the last 10 years were
Builder and Architect, but the traditional
Builder approach is becoming less appealing.
The Architect pathway grew by 30% in the
past five years and is expected to continue
to grow.
Ecosystem and Controller pathways account
for only 16% and 14% of M&A deals but we
anticipate that to increase.
Ecosystem will be utilized more often as
partnerships or M&A – to access capabilities
such as AI that accelerate time-to-market.
Controller will become more popular based
on increased opportunities in China
combined with pricing pressures in the US.
Growth Pathways Predictions
Source: Accenture Research Growth Pathways Model 2021.
An analysis of all M&A transactions of top 30 biopharma companies by revenue, leveraging S&P Cap IQ data.
Percentages were calculated based on # of transactions.
Inorganic growth pathways: 2010-2021, number of transactions
36% 34% 16% 14%
Fewer late-stage
asset-based Builder
pathways.
35% 15% 25% 25%
Future (illustrative)
Architect
Early-stage asset
acquisitions often
with a biotechnology
platform
Builder
Bolt-on-late-
stage asset
acquisitions
Ecosystem
Acquisitions of
know-how and
capabilities to
innovate faster or
reach customers
in new ways
Controller
Geographic
expansion
or vertical
integration
Shift away from
early-stage assets
and towards
platform-based
deals.
More Ecosystem and Controller
pathways thanks to nearly unlimited
funding from VC and PE as well as
increasing opportunities ex-US.
Predictions
Based on our analysis, we believe future successes will involve an increased focus
on platforms (Architect) and capabilities such as AI that support innovation at speed
(Ecosystem).
We identified three key actions companies should take in this new era
of innovation and growth:
1 Combine biotechnology platforms (bio-platforms)
and capabilities to create value.
2 Become a “cross-platform” organization and culture.
3 Create a novel science and technology (S&T) incubator
that reports to C-suite.
Copyright © 2022 Accenture. All rights reserved. 10
10
Combine biotechnology platforms (bio-platforms) and capabilities
to create value:
1
Different bio-platforms can and should help each other evolve in new directions
and create value together.
Ecosystem growth pathways that provide access to computational power, data,
and advanced analytics, as well as digital and automation technologies, help
power bio platforms to develop treatments faster.
Copyright © 2022 Accenture. All rights reserved. 11
11
Three key actions
3 Factors eroding the sustainability of an inorganic growth strategy that relies heavily on M&A
Become a “cross-platform” organization and culture:
2 Bio-platform approaches often include novel modalities which may require
different considerations for manufacturing, clinical trials, regulatory, etc.
Successful companies will learn to enter new modalities faster by evaluating
these considerations early on, such as being able to get clarity on new
manufacturing processes, to overcome the resistance in front of developing
new modalities.
They will learn to develop these assets faster and more efficiently and should be
applied to other bio-platforms and various therapeutic areas (TAs) to increase
speed. As bio-platforms and capabilities go across TAs, biopharma leaders will
need to adjust their operating model including their organization and culture
to realize the full value of their bio-platforms.
Copyright © 2022 Accenture. All rights reserved. 12
12
Three key actions
3 Factors eroding the sustainability of an inorganic growth strategy that relies heavily on M&A
Create a novel science and technology (S&T) incubator that reports
to C-suite:
3
If executed well, the bio-platform strategy will lead to a proliferation of assets
in various therapeutic areas (TAs).
It is not efficient to keep building new TA verticals and therefore biopharma will
need to externally source experts, skill sets, capabilities, and relationships
on demand.
Copyright © 2022 Accenture. All rights reserved. 13
13
Three key actions
3 Factors eroding the sustainability of an inorganic growth strategy that relies heavily on M&A
To read the full report go to accenture.com/sustain-growth
Acknowledgements:
The authors would like to thank Nic Simitzi for his support in forming the overall perspective and performing the analyses in this report;
and Vincenzo Palermo and data science team for the growth pathways AI-algorithm, stock price and biopharma company clustering analyses.
Reach out to the authors to learn more:
Austin Corbett
Managing Director,
Life Sciences Strategy
austin.j.corbett@accenture.com
Kenneth R. Munie
Managing Director,
Life Sciences Strategy Lead
kenneth.r.munie@accenture.com
Stuart Henderson
Senior Managing Director,
Northeast Market Unit Lead
stuart.t.henderson@accenture.com
Selen Karaca-Griffin
Senior Principal,
Global Life Sciences Research Lead
selen.karca-griffin@accenture.com
Dr. Petra Jantzer
Senior Managing Director,
Global Life Sciences Lead
petra.jantzer@accenture.com
Copyright © 2022 Accenture. All rights reserved.

More Related Content

What's hot

More deals, less money: the Black founder funding journey
More deals, less money: the Black founder funding journeyMore deals, less money: the Black founder funding journey
More deals, less money: the Black founder funding journey
accenture
 
Maximizing AI Investments | Accenture
Maximizing AI Investments | AccentureMaximizing AI Investments | Accenture
Maximizing AI Investments | Accenture
accenture
 
Governing Innovation: The recipe for portfolio growth | Accenture
Governing Innovation: The recipe for portfolio growth | AccentureGoverning Innovation: The recipe for portfolio growth | Accenture
Governing Innovation: The recipe for portfolio growth | Accenture
accenture
 
Nonprofit reinvention in a time of unprecedented change
 Nonprofit reinvention in a time of unprecedented change Nonprofit reinvention in a time of unprecedented change
Nonprofit reinvention in a time of unprecedented change
accenture
 
Pathways to Profitability for the Communications Industry
Pathways to Profitability for the Communications IndustryPathways to Profitability for the Communications Industry
Pathways to Profitability for the Communications Industry
accenture
 
The Digital Thread for Life Sciences | Accenture
The Digital Thread for Life Sciences | AccentureThe Digital Thread for Life Sciences | Accenture
The Digital Thread for Life Sciences | Accenture
accenture
 
The Reinvention Reset | Accenture
The Reinvention Reset | AccentureThe Reinvention Reset | Accenture
The Reinvention Reset | Accenture
accenture
 
New Science: Pharma's new growth machine
New Science: Pharma's new growth machineNew Science: Pharma's new growth machine
New Science: Pharma's new growth machine
accenture
 
Digitizing Business Services
Digitizing Business ServicesDigitizing Business Services
Digitizing Business Services
accenture
 
Semiconductor Gender Parity Study
Semiconductor Gender Parity StudySemiconductor Gender Parity Study
Semiconductor Gender Parity Study
accenture
 
Research and Development Solutions | Accenture
Research and Development Solutions | AccentureResearch and Development Solutions | Accenture
Research and Development Solutions | Accenture
accenture
 
The Industrialist: Trends & Innovations - July 2022
The Industrialist: Trends & Innovations - July 2022The Industrialist: Trends & Innovations - July 2022
The Industrialist: Trends & Innovations - July 2022
accenture
 
Growth-Driving Enterprise Innovation Model | Accenture
Growth-Driving Enterprise Innovation Model | AccentureGrowth-Driving Enterprise Innovation Model | Accenture
Growth-Driving Enterprise Innovation Model | Accenture
accenture
 
Technology Trends 2021 | Tech Vision | Accenture
Technology Trends 2021 | Tech Vision | AccentureTechnology Trends 2021 | Tech Vision | Accenture
Technology Trends 2021 | Tech Vision | Accenture
accenture
 
A passwordless enterprise journey
A passwordless enterprise journeyA passwordless enterprise journey
A passwordless enterprise journey
accenture
 
Pivot to the Patient
Pivot to the PatientPivot to the Patient
Pivot to the Patient
accenture
 
INTIENT Patient Solution
INTIENT Patient SolutionINTIENT Patient Solution
INTIENT Patient Solution
accenture
 
The Industrialist: Trends & Innovations - September 2023
The Industrialist: Trends & Innovations - September 2023The Industrialist: Trends & Innovations - September 2023
The Industrialist: Trends & Innovations - September 2023
accenture
 
Reinventing Enterprise Operations
Reinventing Enterprise OperationsReinventing Enterprise Operations
Reinventing Enterprise Operations
accenture
 
Reaching Net Zero by 2050- Canada
Reaching Net Zero by 2050- CanadaReaching Net Zero by 2050- Canada
Reaching Net Zero by 2050- Canada
accenture
 

What's hot (20)

More deals, less money: the Black founder funding journey
More deals, less money: the Black founder funding journeyMore deals, less money: the Black founder funding journey
More deals, less money: the Black founder funding journey
 
Maximizing AI Investments | Accenture
Maximizing AI Investments | AccentureMaximizing AI Investments | Accenture
Maximizing AI Investments | Accenture
 
Governing Innovation: The recipe for portfolio growth | Accenture
Governing Innovation: The recipe for portfolio growth | AccentureGoverning Innovation: The recipe for portfolio growth | Accenture
Governing Innovation: The recipe for portfolio growth | Accenture
 
Nonprofit reinvention in a time of unprecedented change
 Nonprofit reinvention in a time of unprecedented change Nonprofit reinvention in a time of unprecedented change
Nonprofit reinvention in a time of unprecedented change
 
Pathways to Profitability for the Communications Industry
Pathways to Profitability for the Communications IndustryPathways to Profitability for the Communications Industry
Pathways to Profitability for the Communications Industry
 
The Digital Thread for Life Sciences | Accenture
The Digital Thread for Life Sciences | AccentureThe Digital Thread for Life Sciences | Accenture
The Digital Thread for Life Sciences | Accenture
 
The Reinvention Reset | Accenture
The Reinvention Reset | AccentureThe Reinvention Reset | Accenture
The Reinvention Reset | Accenture
 
New Science: Pharma's new growth machine
New Science: Pharma's new growth machineNew Science: Pharma's new growth machine
New Science: Pharma's new growth machine
 
Digitizing Business Services
Digitizing Business ServicesDigitizing Business Services
Digitizing Business Services
 
Semiconductor Gender Parity Study
Semiconductor Gender Parity StudySemiconductor Gender Parity Study
Semiconductor Gender Parity Study
 
Research and Development Solutions | Accenture
Research and Development Solutions | AccentureResearch and Development Solutions | Accenture
Research and Development Solutions | Accenture
 
The Industrialist: Trends & Innovations - July 2022
The Industrialist: Trends & Innovations - July 2022The Industrialist: Trends & Innovations - July 2022
The Industrialist: Trends & Innovations - July 2022
 
Growth-Driving Enterprise Innovation Model | Accenture
Growth-Driving Enterprise Innovation Model | AccentureGrowth-Driving Enterprise Innovation Model | Accenture
Growth-Driving Enterprise Innovation Model | Accenture
 
Technology Trends 2021 | Tech Vision | Accenture
Technology Trends 2021 | Tech Vision | AccentureTechnology Trends 2021 | Tech Vision | Accenture
Technology Trends 2021 | Tech Vision | Accenture
 
A passwordless enterprise journey
A passwordless enterprise journeyA passwordless enterprise journey
A passwordless enterprise journey
 
Pivot to the Patient
Pivot to the PatientPivot to the Patient
Pivot to the Patient
 
INTIENT Patient Solution
INTIENT Patient SolutionINTIENT Patient Solution
INTIENT Patient Solution
 
The Industrialist: Trends & Innovations - September 2023
The Industrialist: Trends & Innovations - September 2023The Industrialist: Trends & Innovations - September 2023
The Industrialist: Trends & Innovations - September 2023
 
Reinventing Enterprise Operations
Reinventing Enterprise OperationsReinventing Enterprise Operations
Reinventing Enterprise Operations
 
Reaching Net Zero by 2050- Canada
Reaching Net Zero by 2050- CanadaReaching Net Zero by 2050- Canada
Reaching Net Zero by 2050- Canada
 

Similar to Biopharma's search for sustainable growth

Syngene Ipo Note - Subscribe for long term gains
Syngene Ipo Note - Subscribe for long term gainsSyngene Ipo Note - Subscribe for long term gains
Syngene Ipo Note - Subscribe for long term gains
IndiaNotes.com
 
Stepping Up the Pace
Stepping Up the PaceStepping Up the Pace
Stepping Up the Pace
Cognizant
 
Genetic Technologies Investor Presentation March 2021
Genetic Technologies Investor Presentation March 2021Genetic Technologies Investor Presentation March 2021
Genetic Technologies Investor Presentation March 2021
RedChip Companies, Inc.
 
Ey beyondborders: unlocking value
Ey beyondborders: unlocking valueEy beyondborders: unlocking value
Ey beyondborders: unlocking value
Frédéric Barillet
 
Matthueu Lamiaux-Enfermedades transmitidas por vectores
Matthueu Lamiaux-Enfermedades transmitidas por vectoresMatthueu Lamiaux-Enfermedades transmitidas por vectores
Matthueu Lamiaux-Enfermedades transmitidas por vectores
Fundación Ramón Areces
 
DuPont Presents at Jefferies 10th Annual Global Industrials Conference
DuPont Presents at Jefferies 10th Annual Global Industrials ConferenceDuPont Presents at Jefferies 10th Annual Global Industrials Conference
DuPont Presents at Jefferies 10th Annual Global Industrials Conference
DupontInv
 
Chemical_innovation_An_investment_for_the_ages
Chemical_innovation_An_investment_for_the_agesChemical_innovation_An_investment_for_the_ages
Chemical_innovation_An_investment_for_the_ages
Tim Biggs
 
Opportunity analysis of life science tools market in India - A srinivas sash...
Opportunity analysis of life science tools market in India - A  srinivas sash...Opportunity analysis of life science tools market in India - A  srinivas sash...
Opportunity analysis of life science tools market in India - A srinivas sash...
Srinivas Sashidhar
 
Top 5 strategy of b2b supply chains trends and opportunities
Top 5 strategy of b2b supply chains trends and opportunitiesTop 5 strategy of b2b supply chains trends and opportunities
Top 5 strategy of b2b supply chains trends and opportunities
globaltradeplaza498
 
Catalent (CTLT) Equity Report
Catalent (CTLT) Equity ReportCatalent (CTLT) Equity Report
Catalent (CTLT) Equity Report
Leon Stempert
 
Investor deck (fy16 q4) final 9.7.16
Investor deck (fy16 q4) final 9.7.16Investor deck (fy16 q4) final 9.7.16
Investor deck (fy16 q4) final 9.7.16
cloroxir2016
 
Emerging Markets Digital Health Outlook 2023.pdf
Emerging Markets Digital Health Outlook 2023.pdfEmerging Markets Digital Health Outlook 2023.pdf
Emerging Markets Digital Health Outlook 2023.pdf
ScallionRice
 
Investor Overview
Investor OverviewInvestor Overview
Investor Overview
cloroxir2016
 
Manufacturing Industry Survey Report
Manufacturing Industry Survey ReportManufacturing Industry Survey Report
Manufacturing Industry Survey Report
Innovations2Solutions
 
Augmedix Equity Research Report - Brendan Hegarty.pdf
Augmedix Equity Research Report - Brendan Hegarty.pdfAugmedix Equity Research Report - Brendan Hegarty.pdf
Augmedix Equity Research Report - Brendan Hegarty.pdf
brendanhegarty4321
 
Whitepaper: Patent strategies in the 2012 economic environment
Whitepaper: Patent strategies in the 2012 economic environmentWhitepaper: Patent strategies in the 2012 economic environment
Whitepaper: Patent strategies in the 2012 economic environment
Sagentia
 
Clx investor presentation
Clx investor presentationClx investor presentation
Clx investor presentation
cloroxir2016
 
Unlocking Trapped Value of Innovation Investments​
Unlocking Trapped Value of Innovation Investments​Unlocking Trapped Value of Innovation Investments​
Unlocking Trapped Value of Innovation Investments​
accenture
 
Medical_Devices_Industry
Medical_Devices_IndustryMedical_Devices_Industry
Medical_Devices_Industry
Virendra K
 
DuPont at J.P. Morgan Aviation, Transportation and Industrials Conference
DuPont at J.P. Morgan Aviation, Transportation and Industrials ConferenceDuPont at J.P. Morgan Aviation, Transportation and Industrials Conference
DuPont at J.P. Morgan Aviation, Transportation and Industrials Conference
DupontInv
 

Similar to Biopharma's search for sustainable growth (20)

Syngene Ipo Note - Subscribe for long term gains
Syngene Ipo Note - Subscribe for long term gainsSyngene Ipo Note - Subscribe for long term gains
Syngene Ipo Note - Subscribe for long term gains
 
Stepping Up the Pace
Stepping Up the PaceStepping Up the Pace
Stepping Up the Pace
 
Genetic Technologies Investor Presentation March 2021
Genetic Technologies Investor Presentation March 2021Genetic Technologies Investor Presentation March 2021
Genetic Technologies Investor Presentation March 2021
 
Ey beyondborders: unlocking value
Ey beyondborders: unlocking valueEy beyondborders: unlocking value
Ey beyondborders: unlocking value
 
Matthueu Lamiaux-Enfermedades transmitidas por vectores
Matthueu Lamiaux-Enfermedades transmitidas por vectoresMatthueu Lamiaux-Enfermedades transmitidas por vectores
Matthueu Lamiaux-Enfermedades transmitidas por vectores
 
DuPont Presents at Jefferies 10th Annual Global Industrials Conference
DuPont Presents at Jefferies 10th Annual Global Industrials ConferenceDuPont Presents at Jefferies 10th Annual Global Industrials Conference
DuPont Presents at Jefferies 10th Annual Global Industrials Conference
 
Chemical_innovation_An_investment_for_the_ages
Chemical_innovation_An_investment_for_the_agesChemical_innovation_An_investment_for_the_ages
Chemical_innovation_An_investment_for_the_ages
 
Opportunity analysis of life science tools market in India - A srinivas sash...
Opportunity analysis of life science tools market in India - A  srinivas sash...Opportunity analysis of life science tools market in India - A  srinivas sash...
Opportunity analysis of life science tools market in India - A srinivas sash...
 
Top 5 strategy of b2b supply chains trends and opportunities
Top 5 strategy of b2b supply chains trends and opportunitiesTop 5 strategy of b2b supply chains trends and opportunities
Top 5 strategy of b2b supply chains trends and opportunities
 
Catalent (CTLT) Equity Report
Catalent (CTLT) Equity ReportCatalent (CTLT) Equity Report
Catalent (CTLT) Equity Report
 
Investor deck (fy16 q4) final 9.7.16
Investor deck (fy16 q4) final 9.7.16Investor deck (fy16 q4) final 9.7.16
Investor deck (fy16 q4) final 9.7.16
 
Emerging Markets Digital Health Outlook 2023.pdf
Emerging Markets Digital Health Outlook 2023.pdfEmerging Markets Digital Health Outlook 2023.pdf
Emerging Markets Digital Health Outlook 2023.pdf
 
Investor Overview
Investor OverviewInvestor Overview
Investor Overview
 
Manufacturing Industry Survey Report
Manufacturing Industry Survey ReportManufacturing Industry Survey Report
Manufacturing Industry Survey Report
 
Augmedix Equity Research Report - Brendan Hegarty.pdf
Augmedix Equity Research Report - Brendan Hegarty.pdfAugmedix Equity Research Report - Brendan Hegarty.pdf
Augmedix Equity Research Report - Brendan Hegarty.pdf
 
Whitepaper: Patent strategies in the 2012 economic environment
Whitepaper: Patent strategies in the 2012 economic environmentWhitepaper: Patent strategies in the 2012 economic environment
Whitepaper: Patent strategies in the 2012 economic environment
 
Clx investor presentation
Clx investor presentationClx investor presentation
Clx investor presentation
 
Unlocking Trapped Value of Innovation Investments​
Unlocking Trapped Value of Innovation Investments​Unlocking Trapped Value of Innovation Investments​
Unlocking Trapped Value of Innovation Investments​
 
Medical_Devices_Industry
Medical_Devices_IndustryMedical_Devices_Industry
Medical_Devices_Industry
 
DuPont at J.P. Morgan Aviation, Transportation and Industrials Conference
DuPont at J.P. Morgan Aviation, Transportation and Industrials ConferenceDuPont at J.P. Morgan Aviation, Transportation and Industrials Conference
DuPont at J.P. Morgan Aviation, Transportation and Industrials Conference
 

More from accenture

The Industrialist: Trends & Innovations - January 2024
The Industrialist: Trends & Innovations - January 2024The Industrialist: Trends & Innovations - January 2024
The Industrialist: Trends & Innovations - January 2024
accenture
 
Accenture Technology Vision - How the trends apply to higher education
Accenture Technology Vision - How the trends apply to higher education Accenture Technology Vision - How the trends apply to higher education
Accenture Technology Vision - How the trends apply to higher education
accenture
 
The Industrialist: Trends & Innovations - July 2023
The Industrialist: Trends & Innovations - July 2023The Industrialist: Trends & Innovations - July 2023
The Industrialist: Trends & Innovations - July 2023
accenture
 
Accenture Technology Vision - How the trends apply to higher education
Accenture Technology Vision - How the trends apply to higher education Accenture Technology Vision - How the trends apply to higher education
Accenture Technology Vision - How the trends apply to higher education
accenture
 
Digital Euro: Implications for the Financial System
Digital Euro: Implications for the Financial SystemDigital Euro: Implications for the Financial System
Digital Euro: Implications for the Financial System
accenture
 
The Industrialist: Trends & Innovations - June 2023
The Industrialist: Trends & Innovations - June 2023The Industrialist: Trends & Innovations - June 2023
The Industrialist: Trends & Innovations - June 2023
accenture
 
The Industrialist: Trends & Innovations - March 2023
The Industrialist: Trends & Innovations - March 2023The Industrialist: Trends & Innovations - March 2023
The Industrialist: Trends & Innovations - March 2023
accenture
 
Free to be 100% me
Free to be 100% meFree to be 100% me
Free to be 100% me
accenture
 
The Industrialist: Trends & Innovations - February 2023
The Industrialist: Trends & Innovations - February 2023The Industrialist: Trends & Innovations - February 2023
The Industrialist: Trends & Innovations - February 2023
accenture
 
Mundo gamer e a oportunidade de entrada pela abordagem do movimento
Mundo gamer e a oportunidade de entrada pela abordagem do movimentoMundo gamer e a oportunidade de entrada pela abordagem do movimento
Mundo gamer e a oportunidade de entrada pela abordagem do movimento
accenture
 
The Industrialist: Trends & Innovations - January 2023
The Industrialist: Trends & Innovations - January 2023The Industrialist: Trends & Innovations - January 2023
The Industrialist: Trends & Innovations - January 2023
accenture
 
Reimagining the Agenda | Accenture
Reimagining the Agenda | AccentureReimagining the Agenda | Accenture
Reimagining the Agenda | Accenture
accenture
 
Climate Leadership Eleventh Hour | Accenture
Climate Leadership Eleventh Hour | AccentureClimate Leadership Eleventh Hour | Accenture
Climate Leadership Eleventh Hour | Accenture
accenture
 
Sustainable Value Chain
Sustainable Value ChainSustainable Value Chain
Sustainable Value Chain
accenture
 
Chemical Companies in the Metaverse
Chemical Companies in the MetaverseChemical Companies in the Metaverse
Chemical Companies in the Metaverse
accenture
 
Sustainable Value Chain
Sustainable Value ChainSustainable Value Chain
Sustainable Value Chain
accenture
 
The Industrialist: Trends & Innovations - November 2022
The Industrialist: Trends & Innovations - November 2022The Industrialist: Trends & Innovations - November 2022
The Industrialist: Trends & Innovations - November 2022
accenture
 
Metaverse opportunities for the communications industry
 Metaverse opportunities for the communications industry Metaverse opportunities for the communications industry
Metaverse opportunities for the communications industry
accenture
 
Retail’s Responsible Reset | Accenture
Retail’s Responsible Reset | AccentureRetail’s Responsible Reset | Accenture
Retail’s Responsible Reset | Accenture
accenture
 
INTIENT Patient
INTIENT Patient INTIENT Patient
INTIENT Patient
accenture
 

More from accenture (20)

The Industrialist: Trends & Innovations - January 2024
The Industrialist: Trends & Innovations - January 2024The Industrialist: Trends & Innovations - January 2024
The Industrialist: Trends & Innovations - January 2024
 
Accenture Technology Vision - How the trends apply to higher education
Accenture Technology Vision - How the trends apply to higher education Accenture Technology Vision - How the trends apply to higher education
Accenture Technology Vision - How the trends apply to higher education
 
The Industrialist: Trends & Innovations - July 2023
The Industrialist: Trends & Innovations - July 2023The Industrialist: Trends & Innovations - July 2023
The Industrialist: Trends & Innovations - July 2023
 
Accenture Technology Vision - How the trends apply to higher education
Accenture Technology Vision - How the trends apply to higher education Accenture Technology Vision - How the trends apply to higher education
Accenture Technology Vision - How the trends apply to higher education
 
Digital Euro: Implications for the Financial System
Digital Euro: Implications for the Financial SystemDigital Euro: Implications for the Financial System
Digital Euro: Implications for the Financial System
 
The Industrialist: Trends & Innovations - June 2023
The Industrialist: Trends & Innovations - June 2023The Industrialist: Trends & Innovations - June 2023
The Industrialist: Trends & Innovations - June 2023
 
The Industrialist: Trends & Innovations - March 2023
The Industrialist: Trends & Innovations - March 2023The Industrialist: Trends & Innovations - March 2023
The Industrialist: Trends & Innovations - March 2023
 
Free to be 100% me
Free to be 100% meFree to be 100% me
Free to be 100% me
 
The Industrialist: Trends & Innovations - February 2023
The Industrialist: Trends & Innovations - February 2023The Industrialist: Trends & Innovations - February 2023
The Industrialist: Trends & Innovations - February 2023
 
Mundo gamer e a oportunidade de entrada pela abordagem do movimento
Mundo gamer e a oportunidade de entrada pela abordagem do movimentoMundo gamer e a oportunidade de entrada pela abordagem do movimento
Mundo gamer e a oportunidade de entrada pela abordagem do movimento
 
The Industrialist: Trends & Innovations - January 2023
The Industrialist: Trends & Innovations - January 2023The Industrialist: Trends & Innovations - January 2023
The Industrialist: Trends & Innovations - January 2023
 
Reimagining the Agenda | Accenture
Reimagining the Agenda | AccentureReimagining the Agenda | Accenture
Reimagining the Agenda | Accenture
 
Climate Leadership Eleventh Hour | Accenture
Climate Leadership Eleventh Hour | AccentureClimate Leadership Eleventh Hour | Accenture
Climate Leadership Eleventh Hour | Accenture
 
Sustainable Value Chain
Sustainable Value ChainSustainable Value Chain
Sustainable Value Chain
 
Chemical Companies in the Metaverse
Chemical Companies in the MetaverseChemical Companies in the Metaverse
Chemical Companies in the Metaverse
 
Sustainable Value Chain
Sustainable Value ChainSustainable Value Chain
Sustainable Value Chain
 
The Industrialist: Trends & Innovations - November 2022
The Industrialist: Trends & Innovations - November 2022The Industrialist: Trends & Innovations - November 2022
The Industrialist: Trends & Innovations - November 2022
 
Metaverse opportunities for the communications industry
 Metaverse opportunities for the communications industry Metaverse opportunities for the communications industry
Metaverse opportunities for the communications industry
 
Retail’s Responsible Reset | Accenture
Retail’s Responsible Reset | AccentureRetail’s Responsible Reset | Accenture
Retail’s Responsible Reset | Accenture
 
INTIENT Patient
INTIENT Patient INTIENT Patient
INTIENT Patient
 

Recently uploaded

Dublin_mulesoft_meetup_Mulesoft_Salesforce_Integration (1).pptx
Dublin_mulesoft_meetup_Mulesoft_Salesforce_Integration (1).pptxDublin_mulesoft_meetup_Mulesoft_Salesforce_Integration (1).pptx
Dublin_mulesoft_meetup_Mulesoft_Salesforce_Integration (1).pptx
Kunal Gupta
 
Vulnerability Management: A Comprehensive Overview
Vulnerability Management: A Comprehensive OverviewVulnerability Management: A Comprehensive Overview
Vulnerability Management: A Comprehensive Overview
Steven Carlson
 
EuroPython 2024 - Streamlining Testing in a Large Python Codebase
EuroPython 2024 - Streamlining Testing in a Large Python CodebaseEuroPython 2024 - Streamlining Testing in a Large Python Codebase
EuroPython 2024 - Streamlining Testing in a Large Python Codebase
Jimmy Lai
 
Data Integration Basics: Merging & Joining Data
Data Integration Basics: Merging & Joining DataData Integration Basics: Merging & Joining Data
Data Integration Basics: Merging & Joining Data
Safe Software
 
High Profile Girls call Service Pune 000XX00000 Provide Best And Top Girl Ser...
High Profile Girls call Service Pune 000XX00000 Provide Best And Top Girl Ser...High Profile Girls call Service Pune 000XX00000 Provide Best And Top Girl Ser...
High Profile Girls call Service Pune 000XX00000 Provide Best And Top Girl Ser...
bhumivarma35300
 
BLOCKCHAIN TECHNOLOGY - Advantages and Disadvantages
BLOCKCHAIN TECHNOLOGY - Advantages and DisadvantagesBLOCKCHAIN TECHNOLOGY - Advantages and Disadvantages
BLOCKCHAIN TECHNOLOGY - Advantages and Disadvantages
SAI KAILASH R
 
WhatsApp Spy Online Trackers and Monitoring Apps
WhatsApp Spy Online Trackers and Monitoring AppsWhatsApp Spy Online Trackers and Monitoring Apps
WhatsApp Spy Online Trackers and Monitoring Apps
HackersList
 
Salesforce AI & Einstein Copilot Workshop
Salesforce AI & Einstein Copilot WorkshopSalesforce AI & Einstein Copilot Workshop
Salesforce AI & Einstein Copilot Workshop
CEPTES Software Inc
 
Introduction-to-the-IAM-Platform-Implementation-Plan.pptx
Introduction-to-the-IAM-Platform-Implementation-Plan.pptxIntroduction-to-the-IAM-Platform-Implementation-Plan.pptx
Introduction-to-the-IAM-Platform-Implementation-Plan.pptx
313mohammedarshad
 
Integrating Kafka with MuleSoft 4 and usecase
Integrating Kafka with MuleSoft 4 and usecaseIntegrating Kafka with MuleSoft 4 and usecase
Integrating Kafka with MuleSoft 4 and usecase
shyamraj55
 
The Rise of AI in Cybersecurity How Machine Learning Will Shape Threat Detect...
The Rise of AI in Cybersecurity How Machine Learning Will Shape Threat Detect...The Rise of AI in Cybersecurity How Machine Learning Will Shape Threat Detect...
The Rise of AI in Cybersecurity How Machine Learning Will Shape Threat Detect...
digitalxplive
 
Figma AI Design Generator_ In-Depth Review.pdf
Figma AI Design Generator_ In-Depth Review.pdfFigma AI Design Generator_ In-Depth Review.pdf
Figma AI Design Generator_ In-Depth Review.pdf
Management Institute of Skills Development
 
CHAPTER-8 COMPONENTS OF COMPUTER SYSTEM CLASS 9 CBSE
CHAPTER-8 COMPONENTS OF COMPUTER SYSTEM CLASS 9 CBSECHAPTER-8 COMPONENTS OF COMPUTER SYSTEM CLASS 9 CBSE
CHAPTER-8 COMPONENTS OF COMPUTER SYSTEM CLASS 9 CBSE
kumarjarun2010
 
The Role of IoT in Australian Mobile App Development - PDF Guide
The Role of IoT in Australian Mobile App Development - PDF GuideThe Role of IoT in Australian Mobile App Development - PDF Guide
The Role of IoT in Australian Mobile App Development - PDF Guide
Shiv Technolabs
 
Litestack talk at Brighton 2024 (Unleashing the power of SQLite for Ruby apps)
Litestack talk at Brighton 2024 (Unleashing the power of SQLite for Ruby apps)Litestack talk at Brighton 2024 (Unleashing the power of SQLite for Ruby apps)
Litestack talk at Brighton 2024 (Unleashing the power of SQLite for Ruby apps)
Muhammad Ali
 
“Deploying Large Language Models on a Raspberry Pi,” a Presentation from Usef...
“Deploying Large Language Models on a Raspberry Pi,” a Presentation from Usef...“Deploying Large Language Models on a Raspberry Pi,” a Presentation from Usef...
“Deploying Large Language Models on a Raspberry Pi,” a Presentation from Usef...
Edge AI and Vision Alliance
 
IPLOOK Remote-Sensing Satellite Solution
IPLOOK Remote-Sensing Satellite SolutionIPLOOK Remote-Sensing Satellite Solution
IPLOOK Remote-Sensing Satellite Solution
IPLOOK Networks
 
How Social Media Hackers Help You to See Your Wife's Message.pdf
How Social Media Hackers Help You to See Your Wife's Message.pdfHow Social Media Hackers Help You to See Your Wife's Message.pdf
How Social Media Hackers Help You to See Your Wife's Message.pdf
HackersList
 
Girls call Kolkata 👀 XXXXXXXXXXX 👀 Rs.9.5 K Cash Payment With Room Delivery
Girls call Kolkata 👀 XXXXXXXXXXX 👀 Rs.9.5 K Cash Payment With Room Delivery Girls call Kolkata 👀 XXXXXXXXXXX 👀 Rs.9.5 K Cash Payment With Room Delivery
Girls call Kolkata 👀 XXXXXXXXXXX 👀 Rs.9.5 K Cash Payment With Room Delivery
sunilverma7884
 
Tirana Tech Meetup - Agentic RAG with Milvus, Llama3 and Ollama
Tirana Tech Meetup - Agentic RAG with Milvus, Llama3 and OllamaTirana Tech Meetup - Agentic RAG with Milvus, Llama3 and Ollama
Tirana Tech Meetup - Agentic RAG with Milvus, Llama3 and Ollama
Zilliz
 

Recently uploaded (20)

Dublin_mulesoft_meetup_Mulesoft_Salesforce_Integration (1).pptx
Dublin_mulesoft_meetup_Mulesoft_Salesforce_Integration (1).pptxDublin_mulesoft_meetup_Mulesoft_Salesforce_Integration (1).pptx
Dublin_mulesoft_meetup_Mulesoft_Salesforce_Integration (1).pptx
 
Vulnerability Management: A Comprehensive Overview
Vulnerability Management: A Comprehensive OverviewVulnerability Management: A Comprehensive Overview
Vulnerability Management: A Comprehensive Overview
 
EuroPython 2024 - Streamlining Testing in a Large Python Codebase
EuroPython 2024 - Streamlining Testing in a Large Python CodebaseEuroPython 2024 - Streamlining Testing in a Large Python Codebase
EuroPython 2024 - Streamlining Testing in a Large Python Codebase
 
Data Integration Basics: Merging & Joining Data
Data Integration Basics: Merging & Joining DataData Integration Basics: Merging & Joining Data
Data Integration Basics: Merging & Joining Data
 
High Profile Girls call Service Pune 000XX00000 Provide Best And Top Girl Ser...
High Profile Girls call Service Pune 000XX00000 Provide Best And Top Girl Ser...High Profile Girls call Service Pune 000XX00000 Provide Best And Top Girl Ser...
High Profile Girls call Service Pune 000XX00000 Provide Best And Top Girl Ser...
 
BLOCKCHAIN TECHNOLOGY - Advantages and Disadvantages
BLOCKCHAIN TECHNOLOGY - Advantages and DisadvantagesBLOCKCHAIN TECHNOLOGY - Advantages and Disadvantages
BLOCKCHAIN TECHNOLOGY - Advantages and Disadvantages
 
WhatsApp Spy Online Trackers and Monitoring Apps
WhatsApp Spy Online Trackers and Monitoring AppsWhatsApp Spy Online Trackers and Monitoring Apps
WhatsApp Spy Online Trackers and Monitoring Apps
 
Salesforce AI & Einstein Copilot Workshop
Salesforce AI & Einstein Copilot WorkshopSalesforce AI & Einstein Copilot Workshop
Salesforce AI & Einstein Copilot Workshop
 
Introduction-to-the-IAM-Platform-Implementation-Plan.pptx
Introduction-to-the-IAM-Platform-Implementation-Plan.pptxIntroduction-to-the-IAM-Platform-Implementation-Plan.pptx
Introduction-to-the-IAM-Platform-Implementation-Plan.pptx
 
Integrating Kafka with MuleSoft 4 and usecase
Integrating Kafka with MuleSoft 4 and usecaseIntegrating Kafka with MuleSoft 4 and usecase
Integrating Kafka with MuleSoft 4 and usecase
 
The Rise of AI in Cybersecurity How Machine Learning Will Shape Threat Detect...
The Rise of AI in Cybersecurity How Machine Learning Will Shape Threat Detect...The Rise of AI in Cybersecurity How Machine Learning Will Shape Threat Detect...
The Rise of AI in Cybersecurity How Machine Learning Will Shape Threat Detect...
 
Figma AI Design Generator_ In-Depth Review.pdf
Figma AI Design Generator_ In-Depth Review.pdfFigma AI Design Generator_ In-Depth Review.pdf
Figma AI Design Generator_ In-Depth Review.pdf
 
CHAPTER-8 COMPONENTS OF COMPUTER SYSTEM CLASS 9 CBSE
CHAPTER-8 COMPONENTS OF COMPUTER SYSTEM CLASS 9 CBSECHAPTER-8 COMPONENTS OF COMPUTER SYSTEM CLASS 9 CBSE
CHAPTER-8 COMPONENTS OF COMPUTER SYSTEM CLASS 9 CBSE
 
The Role of IoT in Australian Mobile App Development - PDF Guide
The Role of IoT in Australian Mobile App Development - PDF GuideThe Role of IoT in Australian Mobile App Development - PDF Guide
The Role of IoT in Australian Mobile App Development - PDF Guide
 
Litestack talk at Brighton 2024 (Unleashing the power of SQLite for Ruby apps)
Litestack talk at Brighton 2024 (Unleashing the power of SQLite for Ruby apps)Litestack talk at Brighton 2024 (Unleashing the power of SQLite for Ruby apps)
Litestack talk at Brighton 2024 (Unleashing the power of SQLite for Ruby apps)
 
“Deploying Large Language Models on a Raspberry Pi,” a Presentation from Usef...
“Deploying Large Language Models on a Raspberry Pi,” a Presentation from Usef...“Deploying Large Language Models on a Raspberry Pi,” a Presentation from Usef...
“Deploying Large Language Models on a Raspberry Pi,” a Presentation from Usef...
 
IPLOOK Remote-Sensing Satellite Solution
IPLOOK Remote-Sensing Satellite SolutionIPLOOK Remote-Sensing Satellite Solution
IPLOOK Remote-Sensing Satellite Solution
 
How Social Media Hackers Help You to See Your Wife's Message.pdf
How Social Media Hackers Help You to See Your Wife's Message.pdfHow Social Media Hackers Help You to See Your Wife's Message.pdf
How Social Media Hackers Help You to See Your Wife's Message.pdf
 
Girls call Kolkata 👀 XXXXXXXXXXX 👀 Rs.9.5 K Cash Payment With Room Delivery
Girls call Kolkata 👀 XXXXXXXXXXX 👀 Rs.9.5 K Cash Payment With Room Delivery Girls call Kolkata 👀 XXXXXXXXXXX 👀 Rs.9.5 K Cash Payment With Room Delivery
Girls call Kolkata 👀 XXXXXXXXXXX 👀 Rs.9.5 K Cash Payment With Room Delivery
 
Tirana Tech Meetup - Agentic RAG with Milvus, Llama3 and Ollama
Tirana Tech Meetup - Agentic RAG with Milvus, Llama3 and OllamaTirana Tech Meetup - Agentic RAG with Milvus, Llama3 and Ollama
Tirana Tech Meetup - Agentic RAG with Milvus, Llama3 and Ollama
 

Biopharma's search for sustainable growth

  • 1. Scientific innovations for more sustainable growth Copyright © 2022 Accenture. All rights reserved.
  • 2. The Situation The pace of innovation in life sciences is at an all time high with unprecedented scientific development in many areas. It’s just the beginning of a significant and lasting shift. With rising M&A costs, increasing pressures on profitability, biotechs bringing products to market themselves, and increasing pressures on profitability, the entire landscape for biopharma has shifted to an environment that requires innovative and strategic approaches to maintain pace. But how can biopharma companies sustain growth?
  • 3. To better understand this challenge and determine pathways for success we conducted an extensive analysis of over 300 M&A deals made by the top 30 biopharma companies between 2010 2021. The key takeaway: The traditional approach to fostering growth is no longer sustainable. The Analysis The good news is that there are clear pathways that biopharma companies can take to remain competitive.
  • 4. Rising Costs of Inorganic Growth: 1 Biotech transaction premiums reached record highs in 2021, making inorganic growth increasingly expensive. For M&A deals valued at more than $500M, the average takeout premium in biopharma has grown from 51% in 2018 to roughly 71% in 2021.1 In Q1 2022, public markets slowed with biotech performance dropping and capital raised decreasing. Nevertheless, private markets remain healthy with total VC investment in Q1 2022 being the second-largest quarter of all time (after Q1 2021) for biotech-venture capital funding.2 How did we get here? 3 Factors eroding the sustainability of an inorganic growth strategy that relies heavily on M&A 1Accenture Research leveraging evaluate Pharma data. March 2022. 2Accenture Research leveraging evaluate Pharma data. April 2022. Copyright © 2022 Accenture. All rights reserved. 4 4
  • 5. Biotech going to market alone: 2 Smaller biotech companies are increasingly able to bring their products to market themselves. These players were responsible for approximately 55% of all drugs brought to market between 2017 and 2021 a significant increase from the preceding five year period (2012 2016) in which they accounted for only 30%.3 Continued venture capital flow to biotechs noted above, further fuels the escalating deal premiums. How did we get here? 3 Factors eroding the sustainability of an inorganic growth strategy that relies heavily on M&A 3Accenture Research leveraging evaluate Pharma data. March 2022. Copyright © 2022 Accenture. All rights reserved. 5 5
  • 6. Increasing profitability pressures: 3 Margin declines in almost every therapeutic area is expected to be over 6% on average, with anti infectives expected to experience the largest decline at 11.6%.4 A further decline in future revenues is also expected due to potential U.S. policy reforms. How did we get here? 3 Factors eroding the sustainability of an inorganic growth strategy that relies heavily on M&A 4New Science: A new economic reality for innovation and growth. Accenture 2021. Copyright © 2022 Accenture. All rights reserved. 6 6
  • 7. Assessing the options Source: Accenture Research Growth Pathways Model 2021. An analysis of all M&A transactions of top 30 biopharma companies by revenue, leveraging S&P Cap IQ data. Percentages were calculated based on # of transactions. Inorganic growth pathways: 2010-2021, number of transactions 36% 34% 16% 14% Controller geographic expansion or vertical integration Ecosystem acquisitions of know-how and capabilities to innovate faster or reach customers in new ways Builder bolt-on-late-stage asset acquisitions Architect early-stage asset acquisitions often with a biotechnology platform Through our analysis, we identified four growth pathways for biopharma companies. By understanding these pathways, we can better anticipate trends toward innovation and success:
  • 8. 1. Architect: Shift away from early-stage assets towards platform-based deals. 2. Builder: Fewer asset-based Builder pathways. 3. Ecosystem and Controller: More Ecosystem and Controller pathways thanks to nearly unlimited funding from VC and PE as well as increasing opportunities ex-US. Growth Pathways Predictions Source: Accenture Research Growth Pathways Model 2021. An analysis of all M&A transactions of top 30 biopharma companies by revenue, leveraging S&P Cap IQ data. Percentages were calculated based on # of transactions. Inorganic growth pathways: 2010-2021, number of transactions 36% 34% 16% 14% Fewer late-stage asset-based Builder pathways. 35% 15% 25% 25% Future (illustrative) Architect Early-stage asset acquisitions often with a biotechnology platform Builder Bolt-on-late- stage asset acquisitions Ecosystem Acquisitions of know-how and capabilities to innovate faster or reach customers in new ways Controller Geographic expansion or vertical integration Shift away from early-stage assets and towards platform-based deals. More Ecosystem and Controller pathways thanks to nearly unlimited funding from VC and PE as well as increasing opportunities ex-US. Predictions
  • 9. 70% of all deals in the last 10 years were Builder and Architect, but the traditional Builder approach is becoming less appealing. The Architect pathway grew by 30% in the past five years and is expected to continue to grow. Ecosystem and Controller pathways account for only 16% and 14% of M&A deals but we anticipate that to increase. Ecosystem will be utilized more often as partnerships or M&A – to access capabilities such as AI that accelerate time-to-market. Controller will become more popular based on increased opportunities in China combined with pricing pressures in the US. Growth Pathways Predictions Source: Accenture Research Growth Pathways Model 2021. An analysis of all M&A transactions of top 30 biopharma companies by revenue, leveraging S&P Cap IQ data. Percentages were calculated based on # of transactions. Inorganic growth pathways: 2010-2021, number of transactions 36% 34% 16% 14% Fewer late-stage asset-based Builder pathways. 35% 15% 25% 25% Future (illustrative) Architect Early-stage asset acquisitions often with a biotechnology platform Builder Bolt-on-late- stage asset acquisitions Ecosystem Acquisitions of know-how and capabilities to innovate faster or reach customers in new ways Controller Geographic expansion or vertical integration Shift away from early-stage assets and towards platform-based deals. More Ecosystem and Controller pathways thanks to nearly unlimited funding from VC and PE as well as increasing opportunities ex-US. Predictions
  • 10. Based on our analysis, we believe future successes will involve an increased focus on platforms (Architect) and capabilities such as AI that support innovation at speed (Ecosystem). We identified three key actions companies should take in this new era of innovation and growth: 1 Combine biotechnology platforms (bio-platforms) and capabilities to create value. 2 Become a “cross-platform” organization and culture. 3 Create a novel science and technology (S&T) incubator that reports to C-suite. Copyright © 2022 Accenture. All rights reserved. 10 10
  • 11. Combine biotechnology platforms (bio-platforms) and capabilities to create value: 1 Different bio-platforms can and should help each other evolve in new directions and create value together. Ecosystem growth pathways that provide access to computational power, data, and advanced analytics, as well as digital and automation technologies, help power bio platforms to develop treatments faster. Copyright © 2022 Accenture. All rights reserved. 11 11 Three key actions 3 Factors eroding the sustainability of an inorganic growth strategy that relies heavily on M&A
  • 12. Become a “cross-platform” organization and culture: 2 Bio-platform approaches often include novel modalities which may require different considerations for manufacturing, clinical trials, regulatory, etc. Successful companies will learn to enter new modalities faster by evaluating these considerations early on, such as being able to get clarity on new manufacturing processes, to overcome the resistance in front of developing new modalities. They will learn to develop these assets faster and more efficiently and should be applied to other bio-platforms and various therapeutic areas (TAs) to increase speed. As bio-platforms and capabilities go across TAs, biopharma leaders will need to adjust their operating model including their organization and culture to realize the full value of their bio-platforms. Copyright © 2022 Accenture. All rights reserved. 12 12 Three key actions 3 Factors eroding the sustainability of an inorganic growth strategy that relies heavily on M&A
  • 13. Create a novel science and technology (S&T) incubator that reports to C-suite: 3 If executed well, the bio-platform strategy will lead to a proliferation of assets in various therapeutic areas (TAs). It is not efficient to keep building new TA verticals and therefore biopharma will need to externally source experts, skill sets, capabilities, and relationships on demand. Copyright © 2022 Accenture. All rights reserved. 13 13 Three key actions 3 Factors eroding the sustainability of an inorganic growth strategy that relies heavily on M&A
  • 14. To read the full report go to accenture.com/sustain-growth Acknowledgements: The authors would like to thank Nic Simitzi for his support in forming the overall perspective and performing the analyses in this report; and Vincenzo Palermo and data science team for the growth pathways AI-algorithm, stock price and biopharma company clustering analyses. Reach out to the authors to learn more: Austin Corbett Managing Director, Life Sciences Strategy austin.j.corbett@accenture.com Kenneth R. Munie Managing Director, Life Sciences Strategy Lead kenneth.r.munie@accenture.com Stuart Henderson Senior Managing Director, Northeast Market Unit Lead stuart.t.henderson@accenture.com Selen Karaca-Griffin Senior Principal, Global Life Sciences Research Lead selen.karca-griffin@accenture.com Dr. Petra Jantzer Senior Managing Director, Global Life Sciences Lead petra.jantzer@accenture.com Copyright © 2022 Accenture. All rights reserved.